Men going bald turn to 'new Botox' for hair loss treatment
The cure for baldness has long been a scientific enigma.
Yet advanced treatment options and hair-loss clinics have continued to emerge — and researchers are making progress on finding fixes for balding.
UCLA scientists recently alerted a "breakthrough" discovery involving a molecule named PP405 that can "waken long-slumbering but undamaged" hair follicles, according to a press release.
In a 2023 clinical trial, researchers found that applying PP405 as a topical medicine to the scalp at bedtime showed "statistically significant" results.
They believe this treatment will produce "full 'terminal' hair rather than the peach fuzz variety."
William Lowry, Ph.D., a co-researcher at UCLA Broad Stem Cell Research Center, told Fox News Digital that although this research is promising, "cure is a strong word."
"There are only two FDA-approved treatments for androgenetic alopecia (AGA, or pattern baldness): minoxidil and finasteride," he said in an interview.
"They are both limited in efficacy and improve hair in only a portion of patients who take them."
Other treatment options include supplements, red light therapy, platelet-rich plasma injections and hair transplantation, Lowry said, although these have not undergone "definitive clinical trials and can be expensive, time-consuming and limited in efficacy."
He added, "None of these are curative, meaning none of them permanently restore all hair lost due to AGA."
Lowry and his fellow researchers have discovered that hair follicle stem cells have a "distinct metabolism from other cells in the follicle."
He said, "We found that promoting this metabolism can accelerate stem cell activation, which makes new hairs grow. We subsequently developed drugs that can drive this effect in various models of hair loss that reflect the multifactorial drivers of androgenetic alopecia in patients."
PP405 has become the leading candidate for hair-loss treatment as part of this new class of drugs.
"We are excited about the opportunity to bring a novel treatment option to patients with hair loss based on strong science and rigorous clinical trials," he said.
"Additionally, because the mechanism of action we discovered is distinct from previous approaches, it can potentially be used in combination with other therapies."
Brendan Camp, M.D., a Manhattan-based dermatologist, told Fox News Digital in an interview that hair loss is a condition that "affects many and can have a negative impact on people's psychosocial health."
So identifying a potential new hair-loss treatment is an "exciting step for patients and providers in the management of what can otherwise be a difficult condition to treat."
Camp agreed there is an "unmet need" for hair-loss treatment and that there's growing interest in providing solutions and offering hair restoration services more widely.
As cosmetic injections such as Botox and fillers have continued to be popular anti-aging and beauty treatments, hair-loss and restoration med spas are similarly surfacing nationwide.
The clinics offer a variety of services for men and women given the availability of modern options.
Dr. Amy Spizuoco, DO, of True Dermatology in New York, dubbed balding treatments in this capacity the "new Botox."
"With advances in treatments like minoxidil, finasteride, PRP (platelet-rich plasma) therapy, hair transplants and the latest stem cell research, hair restoration has become more accessible and effective," she told Fox News Digital.
"And much like Botox is used preventatively, younger people are tackling hair loss at the first signs rather than waiting until it's severe."
Camp added that while there are many hair-loss treatment options available, the response will look different for each person.
"When looking for a treatment, stick to those with a well-established body of evidence and data to support their use, such as minoxidil, finasteride and spironolactone (in the case of female-pattern hair loss)," he advised.
And be sure to get "the advice of a board-certified dermatologist when at-home treatments are not effective," he also said.
These treatments are "typically used indefinitely" and should be tested for three to four months before being ruled out as effective or not, the dermatologist added.
Spizuoco said that while hair loss is common, early intervention with the right treatment plan can "significantly slow it down or possibly reverse it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
14 minutes ago
- CNBC
Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand. Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday. The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ. Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data. Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America. Regencell's market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp. Earlier this month, Regencell explained the stock split as designed solely "to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors." Stock splits do not change anything fundamentally about a company. Regencell's surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines. Regencell's stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day. In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders. Regencell's business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement. Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called "detoxication herbs," blood circulation herbs and digestion herbs. "These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD," Regencell's website reads. In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC. "We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing. Regencell has not responded to a CNBC request for comment. Regencell's latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company's webpage. In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au's modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company's Covid treatment in ASEAN countries, according to the statement. The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism. One user on the Reddit page "r/Shortsqueeze" wrote on Monday that Regencell is "trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol." Another user said in a post made three months ago, "I scalp RGC everyday for a bit of profit." The stock jumped 1,360% in May alone. On LinkedIn in May, one investor said he "can't stop laughing," after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the "stock to watch" after its spike in May on "no official news or catalysts." Another LinkedIn user last month commented on Regencell, saying, "China based, low volume and no official news, bizarro." On X, one user wrote in a Monday post said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
Atlantic
28 minutes ago
- Atlantic
How Ivermectin Became Right-Wing Aspirin
Remember ivermectin? The animal-deworming medication was used so avidly as an off-label COVID treatment during the pandemic that some feed stores ended up going out of stock. (MUST SHOW A PIC OF YOU AND YOUR HORSE, a sign at one demanded of would-be customers in 2021.) If you haven't heard about it since, then you've existed blissfully outside the gyre of misinformation and conspiracies that have come to define the MAGA world's outlook on medicine. In the past few years, ivermectin's popularity has only grown, and the drug has become a go-to treatment for almost any ailment whatsoever. Once a suspect COVID cure, now a right-wing aspirin. In fact, ivermectin never really worked for treating SARS-CoV-2 infections. Many of the initial studies that hinted at a benefit turned out to be flawed and unreliable. By 2023, a series of clinical trials had already proved beyond a doubt that ivermectin won't reduce COVID symptoms or mortality. But these findings mattered little to its fans, who saw the drug as having earned the status of dissident antiviral —a treatment that they believed had been suppressed by the medical establishment. And if ivermectin was good enough to be rejected by mainstream doctors as a cure for COVID, health-care skeptics seemed to reason, then surely it must have a host of other uses too. As a physician who diagnoses cancer, I have come across this line of thinking in my patients, and found that some were using ivermectin to treat their life-threatening tumors. Nicholas Hornstein, a medical oncologist in New York City, told me that he's had the same experience: About one in 20 of his patients ask about the drug, he said. He remembers one woman who came into his office with a tumor that was visibly protruding from her abdomen, having swapped her chemotherapy for some ivermectin that she'd picked up at a veterinary-supply store. 'It's going to work any day now,' he says she told him when he tried to intervene. The idea that ivermectin could be a cancer-fighting agent does have some modest basis in reality: Preliminary studies have suggested that antiparasitic medications might inhibit tumor growth, and at least one ongoing clinical trial is evaluating ivermectin's role as an adjunct to cancer treatment. That study has enrolled only nine patients, however, and the results so far show that just one patient's tumor actually shrank, according to a recent scientific abstract. But these meager grounds for hope now support a towering pile of expectations. Cancer is just one of many illnesses that ivermectin is supposed to heal. According to All Family Pharmacy, a Florida-based company that promotes the compound to fans of Donald Trump Jr., Dan Bongino, Matt Gaetz, and Laura Ingraham on their podcasts and shows, the drug has 'anti-inflammatory properties that could help keep the immune system balanced in fighting infection.' (The company did not respond to a request for comment.) In sprawling Facebook groups devoted to ivermectin's healing powers, the claims are more extreme: The drug can combat a long list of conditions, members say, including Alzheimer's disease, heart disease, diabetes, autism, carpal tunnel syndrome, crow's feet, brain fog, and bee stings. As a medication that supposedly was censored by elites—if not canceled outright by woke medicine and Big Pharma—ivermectin has become a symbol of medical freedom. It's also a MAGA shibboleth: Republican-leaning parts of the country helped drive an astounding 964 percent increase in prescriptions for the drug early in the pandemic, and GOP members of Congress have used their official posts to advocate for its benefits. Ivermectin can now be purchased without a prescription in Arkansas and Idaho, and other states are considering similar measures. Health and Human Services Secretary Robert F. Kennedy Jr. has been a particularly strong proponent. In his 2021 book about the pandemic, Kennedy referred to the 'massive and overwhelming evidence' in ivermectin's favor, and invoked its 'staggering, life-saving efficacy.' He also argued at great length that the pharmaceutical industry—with the support of Anthony Fauci and Bill Gates—had engaged in a historic crime by attempting to discourage its use. Jay Bhattacharya, the director of the National Institutes of Health, has similarly backed the conspiracy theory that the use of ivermectin was dismissed by 'the powers that be' in an apparent ploy to ease the approval of COVID vaccines. (Not everyone in the current administration is a fan: Before he became the FDA's vaccine czar, the oncologist Vinay Prasad publicly disputed Kennedy's views on ivermectin, and earlier this year he called its use for cancer 'the right's version of masking on the airplane and praying to Lord Fauci.') In response to questions about Kennedy's and Bhattacharya's current views on ivermectin, the HHS press secretary Emily Hilliard told me that they 'continue to follow the latest scientific research regarding therapeutic options for COVID-19 and other illnesses.' She did not respond to questions about Prasad. The idea of using antiparasitic drugs as cancer treatments was already taking hold by the late 2010s, Skyler Johnson, a Utah radiation oncologist who studies medical misinformation, told me. In January 2017, a man with lung cancer named Joe Tippens started on a dewormer called fenbendazole, which had been suggested to him by a veterinarian. Daniel Lemoi, who had Lyme disease, had started taking ivermectin in 2012 after reading a paper on the genetic similarities between humans and horses. Tippens would go on to achieve global fame among desperate cancer patients, and Lemoi became an ivermectin influencer during the pandemic. Since then, a gaggle of dubious doctors has worked to bolster the credibility of deworming drugs within alternative medicine and anti-vaccine circles. Their underlying pitch has become familiar in the past few years: Health experts can't be trusted; the pharmaceutical industry is suppressing cheap cures; and patients deserve the liberty to choose their own medical interventions. For the rest of the medical establishment, the worldview this entails is straining doctor-patient relationships. Johnson told me that many of his patients are now skeptical of his advice, if not openly combative. One cancer patient accused Johnson of bias when he failed to recommend ivermectin. The drug is so cheap and effective, this patient had concluded, that Johnson would be out of a job if everyone knew about it. (Johnson told me that he offers patients 'the best possible treatment, no matter the financial incentive.') Ivermectin has become a big business in its own right. Online pharmacies and wellness shops are cashing in on the deworming craze, with one offering parasite cleanses for $200 a month. Meanwhile, fringe doctors can charge patients who have cancer and other diseases thousands of dollars to prescribe such treatments. Johnson's own experience suggests that the cult of ivermectin is growing larger. He told me that he's seen his patients' interest in the drug explode since January, when the actor Mel Gibson went on Joe Rogan's podcast and claimed that three of his friends had beat back their advanced tumors with ivermectin and fenbendazole, among various other potions. 'This stuff works, man,' Gibson said. Meanwhile, in the ivermectin Facebook groups—including one with close to 300,000 members—the public can read posts from a woman with breast cancer considering using ivermectin in lieu of hormone treatments; a leukemia patient who has given up on chemotherapy to ' see what happens ' with antiparasitic drugs; or a concerned aunt wondering if the drugs might help her little niece with Stage 4 cancer. But ivermectin advocacy is most disturbing in its totalizing form, wherein parasites—which is to say, the pathogens against which the drug truly is effective—are reimagined as the secret cause of many other unrelated problems. In the Facebook groups, members will share images of what they say are worms that have been expelled from their bodies by treatment. (This phenomenon brings to mind a different disease entirely: delusional parasitosis.) One recent post from the daughter of a Stage 4 lung-cancer patient showed a bloody glob that had 'dropped down into her mouth.' Commenters debated whether this might be a worm or something else. 'Blood clot from Covid vax?' one suggested. A few days later, the daughter gave an update: Her mom had gone to see the doctor, who informed her that she'd likely coughed up a piece of her own lung. The whole exchange provides a sad illustration of this delirious and desperate time. Before it turned into a conservative cure-all, ivermectin was legitimately a wonder drug for the poorest people on Earth. Since its discovery in 1973, it has become a leading weapon in the fight against horrific infections such as river blindness and elephantiasis. Yet now that substantial success seems to have given birth to a self-destructive fantasy. A decade ago, the co-discoverers of ivermectin—William Campbell and Satoshi Ōmura—were awarded a Nobel Prize in recognition of their contribution to reducing human suffering. In his formal lecture to the Academy, Campbell offered some reflections on the simple science that gave rise to the treatment, and to its wide array of applications. But his speech contained a warning, too, that any medicine that works so broadly and so well runs the risk of being handed out too often. The more benefits that such a drug provides, he told the audience in Stockholm, 'the more we must guard against the hazards of indiscriminate use.'
Business Wire
an hour ago
- Business Wire
Dr. Adam S. Arthur Joins inTRAvent Medical as the Chief Clinical Strategy Officer to Lead Clinical Strategy and Guide Platform Development
BLUE BELL, Pa.--(BUSINESS WIRE)--inTRAvent Medical, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, proudly announces the appointment of Dr. Adam S. Arthur, MD, MPH, as Chief Clinical Strategy Officer (CCSO). In this role, Dr. Arthur will lead the company's clinical strategy for the upcoming launch of inTRAvent's platform for external ventricular drain (EVD) placement, SOLOPASS ®, while guiding the development of additional minimally invasive applications. "Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement." Dr. Arthur brings a wealth of experience to inTRAvent Medical, with a distinguished career in both open cerebrovascular and endovascular neurosurgery. As the James T. Robertson Endowed Professor and Chair of Neurosurgery at the University of Tennessee Health Science Center, and a practicing neurosurgeon at Semmes Murphey Clinic, he has been at the forefront of neurovascular treatment advancements. His leadership in clinical trials, including the pivotal WEB-IT, STEM, and MIND studies, underscores his commitment to advancing innovation to improve patient outcomes. inTRAvent's FDA cleared SOLOPASS ® delivers real-time ultrasound imaging during EVD placement procedures, integrating frameless fixation with a rigid guidance system designed to support precise localization and navigation in critical-care environments. 'Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement,' Arthur said. 'Importantly, this platform also creates a pathway for minimally invasive approaches to treating intracranial hemorrhage – without the need to move critically ill patients from the ICU.' The SOLOPASS system, designed from inception for the critical-care setting, combines 2D and 3D ultrasound imaging, AI, and trajectory guidance to provide real-time intra-procedural localization and navigation – avoiding the limitations of traditional systems, which rely on preoperative images that can become unreliable and no longer reflect actual anatomy due to brain shift or evolving pathology. 'Dr. Arthur's exceptional expertise and forward-thinking approach to neurosurgery make him an invaluable addition to our team,' said inTRAvent Medical's CEO, Adam Barner. 'His insights will help guide the continued clinical development of our SOLOPASS ® platform to address significant unmet clinical needs.' About inTRAvent Medical Partners inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures. Its first product, SOLOPASS®, enables simple, portable neuro-navigation using 2D and 3D ultrasound imaging, artificial intelligence, and trajectory guidance for intra-procedural localization and navigation. For more information, please visit or find us on LinkedIn.
